Survodutide does not raise CV risk in patients with obesity

Coverage, in order

1. 2d ago
   
   Healio indie observational

   Survodutide does not raise CV risk in patients with obesity

   CHICAGO — Survodutide, a novel glucagon/GLP-1 dual agonist, was noninferior to placebo for major adverse cardiovascular events, according to the results of the SYNCHRONIZE-CVOT trial. SYNCHRONIZE-CVOT, presented at the American Heart Association Scientific Sessions and simultaneously published in…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.